Buy Tirzepatide 10mg Bulk Peptide for Weight Loss Research - Wholesale Price

Tirzepatide 10mg is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for research applications in type 2 diabetes and weight management studies. This peptide demonstrates significantly enhanced efficacy in glucose control and weight reduction compared to selective GLP-1 receptor agonists.

The molecular structure of tirzepatide 10mg features a sequence similar to semaglutide with PEG modification on the lys side chain, enhancing water solubility and functional properties. Its primary physiological function involves acting as a dual agonist for GIP and GLP-1 receptors, making it particularly valuable for metabolic research.

Clinical trial data from the SURMOUNT-1 study indicates substantial weight loss results with tirzepatide 10mg, showing an average reduction of 19.5% body weight after 72 weeks of administration. This makes tirzepatide 10mg a significant compound for obesity and overweight research studies.

Tirzepatide 10mg operates through a once-weekly administration protocol, combining the effects of two incretin hormones into a single molecule. This innovative approach represents a new category of research compounds for metabolic disorders.

The product is supplied as a white powder with high purity standards, ensuring consistent results in research environments. Proper storage conditions include maintaining the peptide in a cool, dry, and dark place to preserve stability and efficacy.

Research applications for tirzepatide 10mg extend to various metabolic studies, particularly focusing on its mechanisms for glucose-dependent insulin secretion and weight management pathways. The compound has received regulatory designations to accelerate its development for obesity-related research.

As with all research peptides, tirzepatide 10mg should be handled according to laboratory safety protocols. Researchers should aliquot the peptide according to experimental requirements and avoid repeated freezing and thawing cycles to maintain integrity.

The development of tirzepatide 10mg represents significant advancement in peptide therapeutics for metabolic diseases. Its dual agonist properties offer unique research opportunities for understanding incretin biology and developing new treatment approaches.

This product is intended for research use only and should be handled by qualified professionals in appropriate laboratory settings. All research should comply with relevant regulations and ethical guidelines.